Haemonetics (NYSE: HAE) reported Q1 EPS of $0.25, $0.03 worse than the analyst estimate of $0.28. Revenue for the quarter came in at $210 million versus the consensus estimate of $205.41 million.

For earnings history and earnings-related data on Haemonetics (HAE) click here.